CRANAD-28: A Robust Fluorescent Compound for Visualization of Amyloid Beta Plaques
CRANAD-28, a difluoroboron curcumin analogue, has been demonstrated in earlier reports to successfully label amyloid beta (Aβ) plaques for imaging both ex vivo and in vivo. CRANAD-28’s imaging brightness, ability to penetrate the blood brain barrier, and low toxicity make the comp...
Main Authors: | Kathleen Ran, Jing Yang, Anil V. Nair, Biyue Zhu, Chongzhao Ran |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/25/4/863 |
Similar Items
-
In-vitro and in-vivo characterization of CRANAD-2 for multi-spectral optoacoustic tomography and fluorescence imaging of amyloid-beta deposits in Alzheimer mice
by: Ruiqing Ni, et al.
Published: (2021-09-01) -
Intranasal neprilysin rapidly eliminates amyloid-beta plaques, but causes plaque compensations: the explanation why the amyloid-beta cascade may fail?
by: Christian Humpel
Published: (2022-01-01) -
Quantitative detection of grey and white matter amyloid pathology using a combination of K114 and CRANAD-3 fluorescence
by: Anastasiia A. Stepanchuk, et al.
Published: (2021-12-01) -
Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer’s disease
by: David L. Brody, et al.
Published: (2017-08-01) -
The amyloid plaque proteome in early onset Alzheimer’s disease and Down syndrome
by: Eleanor Drummond, et al.
Published: (2022-04-01)